国药现代: 2025年第二次临时股东会会议资料

Core Points - The Shanghai Modern Pharmaceutical Co., Ltd. is holding its second extraordinary general meeting of shareholders in 2025 to ensure the orderly conduct of the meeting and protect shareholders' rights [1][2] - The meeting will include the election of a new board member and the revision of the "Management Measures for the Use of Raised Funds" [3][4] Meeting Details - The meeting is scheduled for September 15, 2025, at 14:30, located at the company's office in Shanghai [2] - Attendees will include registered shareholders, company directors, senior management, and legal representatives [2] Agenda Items - Election of Directors: The board has nominated Mr. Cai Maisong as a candidate for the board of directors, pending shareholder approval [3][4] - Revision of Fund Management Guidelines: The company proposes to amend its "Management Measures for the Use of Raised Funds" to enhance operational standards and compliance with regulatory requirements [4][14] Key Revisions in Fund Management - The revised guidelines specify that raised funds must be used exclusively for disclosed investment projects and cannot be used for supplementing working capital or repaying bank loans [4][11] - The management of raised funds must adhere to principles of safety, efficiency, and transparency [14][15] - The company must establish a dedicated account for raised funds, ensuring that these funds are not mixed with other financial resources [15][16] Compliance and Reporting - The company is required to provide detailed reports on the use of raised funds, including any changes in project timelines or funding allocations [19][30] - Independent auditors will review the management and usage of raised funds annually, ensuring compliance with the revised guidelines [30][32]